MA44728A - Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains - Google Patents

Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains

Info

Publication number
MA44728A
MA44728A MA044728A MA44728A MA44728A MA 44728 A MA44728 A MA 44728A MA 044728 A MA044728 A MA 044728A MA 44728 A MA44728 A MA 44728A MA 44728 A MA44728 A MA 44728A
Authority
MA
Morocco
Prior art keywords
betabloquant
antihypertenseur
nsaid
pharmaceutical composition
composition consisting
Prior art date
Application number
MA044728A
Other languages
English (en)
Inventor
Gilles Fonknechten
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MA44728A publication Critical patent/MA44728A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA044728A 2016-04-20 2017-04-19 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains MA44728A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1653502A FR3050380B1 (fr) 2016-04-20 2016-04-20 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains.

Publications (1)

Publication Number Publication Date
MA44728A true MA44728A (fr) 2019-02-27

Family

ID=56943614

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044728A MA44728A (fr) 2016-04-20 2017-04-19 Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains

Country Status (14)

Country Link
EP (1) EP3445342A1 (fr)
KR (1) KR102267965B1 (fr)
CN (1) CN109069438A (fr)
BR (1) BR112018070968A2 (fr)
EA (1) EA201892354A1 (fr)
FR (1) FR3050380B1 (fr)
GE (1) GEP20217310B (fr)
MA (1) MA44728A (fr)
PH (1) PH12018502155A1 (fr)
RU (1) RU2756320C2 (fr)
SG (2) SG11201808848SA (fr)
TN (1) TN2018000344A1 (fr)
UA (1) UA125511C2 (fr)
WO (1) WO2017182754A1 (fr)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (de) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
FR2503155A2 (fr) 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2620709B1 (fr) 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
FR2807431B1 (fr) 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
AR036187A1 (es) 2001-07-24 2004-08-18 Adir Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario
FR2827860B1 (fr) 2001-07-24 2004-12-10 Servier Lab Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
DK1333026T3 (da) 2002-01-30 2007-10-22 Servier Lab Fremgangsmåde til fremstilling af perindopril med höj renhed og nyttige mellemforbindelser til syntesen
FR2838648B1 (fr) 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
WO2004075889A1 (fr) 2003-02-28 2004-09-10 Lupin Limited Procede de preparation de perindopril et de sels de celui-ci
EP1403275B1 (fr) 2003-02-28 2005-10-19 Les Laboratoires Servier Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
EP1321471B1 (fr) 2003-03-12 2005-05-04 Les Laboratoires Servier Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables
ES2286393T3 (es) 2003-06-30 2007-12-01 Les Laboratoires Servier Nuevo procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables.
DE60303101T2 (de) 2003-06-30 2006-09-28 Les Laboratoires Servier Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen
US20050026992A1 (en) * 2003-07-28 2005-02-03 Sasmal Badal Kumar Treatment and prevention of cardiovascular events
SI1367063T1 (sl) 2003-07-31 2006-10-31 Servier Lab Nov postopek sinteze perindoprila in njegovih farmacevtsko sprejemljivih soli
SI1367062T1 (sl) 2003-07-31 2006-12-31 Servier Lab Nov postopek sinteze perindoprila in njegovih farmacevtsko sprejemljivih soli
SI1371659T1 (sl) 2003-08-29 2006-02-28 Servier Lab Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
DK1380590T3 (da) 2003-08-29 2007-01-08 Servier Lab Ny fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf
DK1380591T3 (da) 2003-08-29 2006-01-23 Servier Lab Fremgangsmåde til syntese af perindopril og farmaceutiske acceptable salte heraf
ES2282586T3 (es) 2003-11-19 2007-10-16 Les Laboratoires Servier Procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables.
DE60311730T2 (de) 2003-11-19 2007-12-06 Les Laboratoires Servier Verfahren für die Synthese von Perindopril und seinen pharmazeutisch annehmbaren Salzen
ES2300555T3 (es) 2003-12-10 2008-06-16 Les Laboratoires Servier Procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables.
SI21800A (sl) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
FR2894825B1 (fr) 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2897865B1 (fr) 2006-02-28 2008-04-18 Servier Lab Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2897866B1 (fr) 2006-02-28 2008-04-18 Servier Lab Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN101024082A (zh) * 2007-04-06 2007-08-29 张士东 一种全面预防和治疗心脑血管疾病复方药及其应用
PL2318365T3 (pl) 2008-06-24 2016-02-29 Mylan Laboratories Ltd Nowe odmiany polimorficzne (L) argininianu peryndoprylu i sposoby ich wytwarzania
HU230877B1 (hu) 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
NZ595127A (en) * 2009-02-11 2013-08-30 Cadila Pharmaceuticals Ltd Stable pharmaceutical composition for atherosclerosis
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
FR2961105B1 (fr) 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
FR2985511B1 (fr) 2012-01-05 2014-01-03 Servier Lab Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
CN109069438A (zh) 2018-12-21
EP3445342A1 (fr) 2019-02-27
BR112018070968A2 (pt) 2019-01-29
KR20180132911A (ko) 2018-12-12
FR3050380A1 (fr) 2017-10-27
SG11201808848SA (en) 2018-11-29
FR3050380B1 (fr) 2020-07-10
KR102267965B1 (ko) 2021-06-21
UA125511C2 (uk) 2022-04-13
RU2018140193A3 (fr) 2020-06-03
TN2018000344A1 (en) 2020-06-15
SG10202009894PA (en) 2020-11-27
EA201892354A1 (ru) 2019-04-30
GEP20217310B (en) 2021-11-10
PH12018502155A1 (en) 2019-07-15
WO2017182754A1 (fr) 2017-10-26
RU2018140193A (ru) 2020-05-20
RU2756320C2 (ru) 2021-09-29

Similar Documents

Publication Publication Date Title
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA49043A (fr) Formulation stable d'anticorps
MA46525A (fr) Anticorps anti-lag-3 et compositions
DK3331864T3 (da) 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
EP3524603A4 (fr) Inhibiteur de fgfr4, son procédé de préparation et son utilisation pharmaceutique
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
DK3328844T3 (da) 1,3,4-oxadiazolsulfamidderivater som histondeacetylase-6-inhibitor og farmaceutisk sammensætning omfattende samme
DK3362445T3 (da) Oxadiazolaminderivatforbindelser som histondeacetylase 6-inhibitor, og den farmaceutiske sammensætning dermed
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA44671A (fr) Associations et méthodes comprenant un inhibiteur d'ensemble capside
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MA46109A (fr) Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes
MA43402A (fr) Composition pharmaceutique comprenant un inhibiteur puissant d'urat1
MA54052A (fr) Formulation d'anticorps
MA43705A (fr) Formulation pharmaceutique
MA54139A (fr) Formulation d'anticorps
MA47516A (fr) Composition pharmaceutique
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
BR112017001888A2 (pt) formulações biológicas para instilação intravesical